Products - Stomach cancer | Topic | NICE

Showing 19 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter

Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
23 June 2015
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 September 2023
Oesophago-gastric cancer: assessment and management in adults (NG83)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
4 July 2023
Published:
24 January 2018
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 April 2023
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach (IPG717)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
2 March 2022
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 September 2021
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 June 2019
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 November 2017
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 November 2014
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2010
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 November 2010
Published:
27 October 2004
Capecitabine for the treatment of advanced gastric cancer (TA191)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2010
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 September 2009
Laparoscopic gastrectomy for cancer (IPG269)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 July 2008
Oesophago-gastric cancer (QS176)
Product type:
Quality standard
Published:
13 December 2018
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016